| Literature DB >> 22046186 |
Sharma Gaurav1, Pai M Keerthilatha, Nagpal Archna.
Abstract
The objective of the present research was to determine the prevalence of oral manifestations in an HIV infected population from south India and evaluate their association with HIV viral load and CD4/CD8 ratio. Intraoral examination of 103 patients, whose CD4/CD8 ratio was available, were conducted. HIV viral loads were available for thirty patients only. The prevalence of oral manifestations was 80.6% (83/103). The most common oromucosal lesion was erythematous candidiasis (EC) (38.8%) followed by melanotic hyperpigmentation (35.9%). Patients having any oral manifestation had a mean CD4/CD8 ratio of 0.24. EC had positive predictive value of 85.0% for CD4/CD8 ratio <0.30. The prevalence of oral manifestations in patients taking ART was lesser (78.6%) as compared to patients not taking ART (82%). Patients having any oral manifestation had a higher HIV viral load as compared to patients not having any oral manifestations (P < 0.05). Pseudomembranous candidiasis (PC) was significantly associated with higher HIV viral loads (>20,000 copies/mL) (P < 0.05). Patients having EC had 4 times greater chance of having CD4/CD8 ratio <0.30. PC can be considered as a marker of immune suppression (HIV viral load >20,000 copies/mL).Entities:
Year: 2011 PMID: 22046186 PMCID: PMC3199184 DOI: 10.1155/2011/964278
Source DB: PubMed Journal: Int J Dent ISSN: 1687-8728
Demographics and laboratory parameters of study cohort.
| Variable | Total no. of patients ( | No. of patients with oral manifestations (83/103) |
|---|---|---|
| Gender | ||
| Male | 70 | 58 (82.9%) |
| Female | 33 | 25 (75.8%) |
| Mode of transmission | ||
| Heterosexual mode | 101 | 81 (80.1%) |
| Homosexual mode | 2 | 2 (100%) |
| Antiretroviral therapy | ||
| Yes | 42 | 33 (78.6%) |
| No | 61 | 50 (82.0%) |
| Smoker | ||
| Yes | 32 | 29 (90.6%) |
| No | 71 | 54 (76.1%) |
| Alcohol consumption | ||
| Yes | 48 | 39 (81.3%) |
| No | 55 | 44 (80%) |
| Absolute CD4/CD8 ratio staging | ||
| Group I (0.01–0.30) | 69 | 61 (88.4%) |
| Group II (0.31–0.60) | 28 | 18 (64.2%) |
| Group III (>0.60) | 6 | 04 (66.7%) |
Absolute mean CD4 and CD8 counts along with mean CD4/CD8 ratio of study cohort.
| Clustering of patients according to CD4/CD8 ratio | Mean absolute CD4 count (cells/mm3) | Mean absolute CD8 count (cells/mm3) | Mean CD4/CD8 ratio |
|---|---|---|---|
| Group I (0.01–0.30) ( | 163.43 | 1053.1 | 0.15 |
| Group II (0.31–0.60) ( | 325.00 | 889.1 | 0.39 |
| Group III (>0.60) ( | 502.33 | 659.8 | 0.93 |
| Total no. of patients ( | 228.82 | 988.6 | 0.26 |
Oral manifestations in relation to CD4/CD8 ratio.
| Oral manifestations | Group I | Group II | Group III | Total |
|---|---|---|---|---|
|
|
|
| ( | |
| Any oral manifestation* | 61 (88.4%) | 18 (64.3%) | 4 (66.7%) | 83 (80.6%) |
| Erythematous candidiasis (EC) | 34 (49.3%) | 5 (17.9%) | 1 (16.7%) | 40 (38.8%) |
| Pseudomembranous candidiasis (PC) | 7 (10.1%) | 2 (7.1%) | — | 9 (8.7%) |
| Hyperpigmentation | 28 (40.6%) | 8 (28.6%) | 1 (16.7%) | 37 (35.9%) |
| Oral hairy leukoplakia (OHL) | 14 (20.3%) | 3 (10.7%) | 1 (16.7%) | 18 (17.5%) |
| Necrotizing ulcerative gingivitis (NUG) | 8 (11.6%) | 2 (7.1%) | — | 10 (9.7%) |
| Necrotizing ulcerative periodontitis (NUP) | 3 (4.3%) | — | 1 (16.7%) | 4 (3.9%) |
| Linear gingival erythema (LGE) | 12 (17.4%) | 2 (7.4%) | — | 14 (13.6%) |
| Xerostomia | 26 (37.7%) | 5 (17.9%) | 2 (33.3%) | 33 (32.0%) |
| Angular cheilitis (AC) | 6 (8.7%) | — | — | 6 (5.8%) |
| Apthous ulcers | 4 (5.7%) | 1 (3.6%) | — | 5 (4.9%) |
| Exfoliative cheilitis | 2 (2.8%) | — | — | 2 (1.9%) |
| Hyperplastic candidiasis | 1 (1.4%) | 1 (3.6%) | — | 2 (1.9%) |
| Herpes zoster | 1 (1.4%) | 1 (3.6%) | — | 2 (1.9%) |
*Many patients had more than one oral manifestation.
Mean CD4/CD8 ratio and their association with presence or absence of oral manifestations.
| Oral manifestations (OM) | Mean absolute CD4 count when respective OM present (cells/mm3) | Mean CD4/CD8 ratio of group when respective OM present | Mean CD4/CD8 ratio of group when respective OM absent |
|
|
|---|---|---|---|---|---|
| Any oral manifestation | 196.18 | 0.24 (S.D—0.23) | 0.35 (S.D—0.17) | 3.2 | .01a |
| EC | 147.18 | 0.18 (S.D—0.12) | 0.32 (S.D—0.26) | 3.73 | .00a |
| PC | 126.78 | 0.16 (S.D—0.15) | 0.27 (S.D—0.23) | 1.8 | .05a |
| OHL | 149.39 | 0.26 (S.D—0.23) | 0.26 (S.D—0.22) | .08 | .93b |
| Hyperpigmentation | 192.27 | 0.23 (S.D—0.26) | 0.28 (S.D—0.20) | 1.7 | .08b |
| Xerostomia | 195.7 | 0.22 (S.D—0.17) | 0.29 (S.D—0.24) | 1.8 | .07b |
S.D: Standard deviation.
aStatistically significant.
bNot statistically significant.
Predictive values of oral manifestations for CD4/CD8 ratio <0.30.
| Oral manifestation | PPV | NPV | Odds ratio | 95% CI |
|
|---|---|---|---|---|---|
| EC | 85.0% | 44.4% | 4.53 | 1.66–12.32 | .003a |
| OHL | 77.8% | 35.3% | 1.90 | 0.57–6.31 | .290b |
| Hyperpigmentation | 75.7% | 37.9% | 1.98 | 0.77–4.66 | .164b |
| Xerostomia | 78.8% | 38.6% | 2.33 | 0.89–6.11 | .085b |
| NUG | 80.0% | 34.4% | .477 | 0.09–2.37 | .366b |
| PC | 77.8% | 34.0% | 1.80 | 0.35–9.91 | .477b |
| LGE | 85.7% | 36.0% | 3.36 | 0.70–16.00 | .127b |
PPV: Positive predictive value, NPV: Negative predictive value.
aStatistically significant.
bNot statistically significant.
Comparison of oral manifestations with respect to HIV viral load subpopulation.
| Oral manifestations | HIV viral load <20,000 copies/mL | HIV viral load >20,000 copies/mL | Total |
|
|---|---|---|---|---|
|
|
|
| ||
| Any oral manifestation | 9 (64.3%) | 16 (100%) | 25 (83.3%) | .00a |
| EC | 2 (14.2%) | 10 (62.5%) | 12 (40.0%) | .07b |
| Hyperpigmentation | 3 (21.4%) | 5 (31.2%) | 8 (26.6%) | .54b |
| Xerostomia | 2 (14.2%) | 7 (43.8%) | 9 (30.0%) | .07b |
| OHL | 2 (14.2%) | 2 (12.5%) | 4 (13.3%) | .88b |
| PC | — | 5 (31.2%) | 5 (16.6%) | .02a |
| AC | — | 2 (12.5%) | 2 (6.6%) | — |
| LGE | 2 (14.2%) | — | 2 (6.6%) | — |
| NUG | — | 2 (12.5%) | 2 (6.6%) | — |
| Hyperplastic candidiasis | — | 1 (6.2%) | 1 (3.3%) | — |
aStatistically significant.
bNot statistically significant.
Comparison of oral manifestations with respect to antiretroviral therapy.
| Oral manifestation (OM) | Patients with OM on antiretroviral therapy (ART) | Patients with OM |
|
|---|---|---|---|
|
|
| ||
| Any oral manifestation | 33 (78.6%) | 50 (82%) | .66a |
| EC | 15 (35.7%) | 25 (41.0%) | .59a |
| OHL | 4 (9.5%) | 14 (23.0%) | .07a |
| AC | 2 (4.8%) | 4 (6.6%) | .70a |
| PC | 3 (7.1%) | 6 (9.8%) | .63a |
| Hyperpigmentation | 17 (40.5%) | 20 (32.8%) | .42a |
| Xerostomia | 12 (28.6%) | 21 (34.4%) | .53a |
| LGE | 5 (11.9%) | 9 (14.8%) | .67a |
| NUG | 5 (11.9%) | 5 (8.2%) | .53a |
| NUP | 1 (2.4%) | 3 (4.9%) | .51a |
aNot statistically significant.